Loading clinical trials...
Loading clinical trials...
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Conditions
Interventions
MRD and clonal evolution
Locations
14
Italy
Divisione di Ematologia Ospedale Niguarda
Milan, MI, Italy
SOS Ematologia Ospedale C. Massaia
Asti, Italy
IRCCS Istituto Tumori Giovanni Paolo II - UOC Ematologia
Bari, Italy
AOU Università degli Studi della Campania Luigi Vanvitelli
Naples, Italy
I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1
Padua, Italy
A.O. Universitaria Di Parma
Parma, Italy
Start Date
August 28, 2018
Primary Completion Date
October 6, 2020
Completion Date
October 2, 2025
Last Updated
November 18, 2025
NCT07387471
NCT06510491
NCT01804686
NCT02269592
NCT05602363
NCT07231952
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions